Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset Published September 2019 Citation Backenroth D, Shao C, Li G, Huang L,Pruitt SK, Castellanos EH, Frampton GM, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin FJ, Zhou W. . ESMO Annual Congress. . https://www.sciencedirect.com/science/article/pii/S0923753419600062 Authors:Backenroth D, Shao C, Li G, Huang L,Pruitt SK, Castellanos EH, Frampton GM, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin FJ, Zhou W Sources:ESMO Annual Congress Share Posted inPublicationsDrug discoveryTumor agnostic More publicationsESMO OpenSeptember 2025Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practiceRugo H, Layman R, Lynce F, et al.Publication summaryPublicationsComparative effectivenessMetastatic breast cancerBreast cancerWorld Conference on Lung CancerAugust 2025Disease burden and rwPFS as a surrogate endpoint for rwOS in NTRK+ NSCLC and other advanced/metastatic solid tumorFlores Avile C, Su I-H, Huang P-C, Cho-Phan C, Camidge R, Yuan Y.Publication summaryPublicationsNon-small cell lung cancerWorld Conference on Lung CancerAugust 2025Evolving treatment patterns in early-stage non-small cell lung cancer in the USGray J E, Thoele K, Gilligan A M, et al.Publication summaryPublicationsTreatment patternsNon-small cell lung cancer